Comparison · NCT01718873-sae
Bevacizumab Before Chemotherapy vs Bevacizumab With Chemotherapy: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Bevacizumab Before Chemotherapy vs Bevacizumab With Chemotherapy: serious adverse events. Trial comparisons, record NCT01718873-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01718873-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.565 | 0.474 | 0.652 | wilson | |
| Risk in group 2 | 0.652 | 0.561 | 0.733 | wilson | |
| Risk difference, group 1 minus group 2 | -0.087 | -0.209 | 0.0387 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.867 | 0.703 | 1.07 | log | |
| Odds ratio, group 1 over group 2 | 0.693 | 0.407 | 1.18 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Bevacizumab Before Chemotherapy than on Bevacizumab With Chemotherapy | 11.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Bevacizumab Before Chemotherapy | Bevacizumab administered 4 days before each cycle of chemotherapy containing oxaliplatin (mFOLFOX-6 / mOXXEL)~Bevacizumab: 5 mg/kg every 2 weeks for up to 24 weeks. After 24 weeks, those patients without disease progression will receive bevacizumab 7.5 mg/kg every 3 weeks until progression of disease or unacceptable toxicity.~Oxaliplatin: 85mg/m2 IV every 2 weeks for up to 24 weeks~levo-folinic acid: 200 mg/m2 IV before 5-fluorouracil infusion, every 2 weeks up to 24 weeks~5-fluorouracil: 400 mg/m2 IV bolus followed by 2400 mg/m2 IV infusion over 46 hours, every 2 weeks for up to 24 weeks (given in mFOLFOX-6 schedule)~Capecitabine: 1000mg/m2 by mouth, twice a day for 10 days, every 2 weeks for up to 24 weeks(given in mOXXEL schedule) | 65 | 115 | EG000 |
| Group 2 | Bevacizumab With Chemotherapy | Bevacizumab administered on the first day of each cycle of chemotherapy containing oxaliplatin (mFOLFOX-6 / mOXXEL)~Bevacizumab: 5 mg/kg every 2 weeks for up to 24 weeks. After 24 weeks, those patients without disease progression will receive bevacizumab 7.5 mg/kg every 3 weeks until progression of disease or unacceptable toxicity.~Oxaliplatin: 85mg/m2 IV every 2 weeks for up to 24 weeks~levo-folinic acid: 200 mg/m2 IV before 5-fluorouracil infusion, every 2 weeks up to 24 weeks~5-fluorouracil: 400 mg/m2 IV bolus followed by 2400 mg/m2 IV infusion over 46 hours, every 2 weeks for up to 24 weeks (given in mFOLFOX-6 schedule)~Capecitabine: 1000mg/m2 by mouth, twice a day for 10 days, every 2 weeks for up to 24 weeks(given in mOXXEL schedule) | 75 | 115 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Evaluated every 2 weeks up to 6 months
Source ClinicalTrials.gov
Trial
- Title
- Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer
- NCT number
- NCT01718873
- Phases
- PHASE3
- Conditions
- Colorectal Cancer
- Interventions
- Bevacizumab, Oxaliplatin, levo-folinic acid, 5-fluorouracil, Capecitabine
- Lead sponsor
- National Cancer Institute, Naples
- Results first posted
- 2023-04-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01718873?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01718873-sae